Conduit Pharmaceuticals Enters Material Agreement, Discloses Equity Sales
Ticker: CDTTW · Form: 8-K · Filed: Dec 17, 2024 · CIK: 1896212
| Field | Detail |
|---|---|
| Company | Conduit Pharmaceuticals Inc. (CDTTW) |
| Form Type | 8-K |
| Filed Date | Dec 17, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $11.50, $200,000, $1,800,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, corporate-update
TL;DR
Conduit Pharma inked a deal & sold some stock. Details in the 8-K.
AI Summary
Conduit Pharmaceuticals Inc. announced on December 12, 2024, that it entered into a material definitive agreement. The company also disclosed unregistered sales of equity securities and provided financial statements and exhibits. Conduit Pharmaceuticals Inc. was formerly known as Murphy Canyon Acquisition Corp. until November 30, 2021.
Why It Matters
This filing indicates significant corporate activity, including a new agreement and equity transactions, which could impact the company's financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing involves a material definitive agreement and unregistered equity sales, which can introduce financial and regulatory risks.
Key Players & Entities
- Conduit Pharmaceuticals Inc. (company) — Registrant
- Murphy Canyon Acquisition Corp. (company) — Former company name
- December 12, 2024 (date) — Date of earliest event reported
- November 30, 2021 (date) — Date of name change
FAQ
What is the nature of the material definitive agreement entered into by Conduit Pharmaceuticals Inc.?
The filing does not specify the details of the material definitive agreement, only that one was entered into on December 12, 2024.
What type of equity securities were sold in the unregistered sales by Conduit Pharmaceuticals Inc.?
The filing mentions unregistered sales of equity securities but does not specify the type of securities.
When did Conduit Pharmaceuticals Inc. change its name from Murphy Canyon Acquisition Corp.?
The company changed its name from Murphy Canyon Acquisition Corp. on November 30, 2021.
What is the Central Index Key (CIK) for Conduit Pharmaceuticals Inc.?
The Central Index Key for Conduit Pharmaceuticals Inc. is 0001896212.
What is the Standard Industrial Classification (SIC) code for Conduit Pharmaceuticals Inc.?
The Standard Industrial Classification code for Conduit Pharmaceuticals Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,149 words · 5 min read · ~4 pages · Grade level 12.2 · Accepted 2024-12-17 17:15:19
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share CDT The Nasdaq
- $11.50 — of Common Stock at an exercise price of $11.50 CDTTW The Nasdaq Stock Market LLC
- $200,000 — pay Sarborg an initial cash payment of $200,000 and $200,000 payable through the issuan
- $1,800,000 — e term of the Agreement, totaling up to $1,800,000, are payable in cash or shares, at the
Filing Documents
- form8-k.htm (8-K) — 51KB
- ex10-1.htm (EX-10.1) — 166KB
- ex99-1.htm (EX-99.1) — 14KB
- ex10-1_001.jpg (GRAPHIC) — 188KB
- 0001493152-24-050443.txt ( ) — 752KB
- cdt-20241212.xsd (EX-101.SCH) — 4KB
- cdt-20241212_def.xml (EX-101.DEF) — 29KB
- cdt-20241212_lab.xml (EX-101.LAB) — 36KB
- cdt-20241212_pre.xml (EX-101.PRE) — 27KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 17, 2024 CONDUIT PHARMACEUTICALS INC. By: /s/ Dr. David Tapolczay Name: Dr. David Tapolczay Title: Chief Executive Officer